← Leaderboards
Ann F Mohrbacher
University Of Southern California
$401,972
Attributed
$401,972
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $155K · FY2006–08$200K$150K$100K$50K$0
'06
'07
'08
Funding mix
By agency
NIH$401,972 · 3
By mechanism
M01$401,972 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Robert C Seeger$12,536,093
- Yves A Declerck$18,916,589
- Simon Andrew Gayther$9,015,265
- Jeffrey S Weber$20,866,039
- Don J Diamond$24,317,616
Others in their field
Top investigators on “Adult”
- Lawrence Corey · Fred Hutchinson Cancer Center$594,628,824
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$397,114,680
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$388,038,550
- Judith S. Currier · University Of California Los Angeles$251,592,913
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$196,603,707
- Carol Nesel · Westat$188,148,170
Research focus
AdultBiological AvailabilityBreastCell LineChildClinical Trials, Phase IComputer Retrieval Of Information On Scientific Projects DatabaseCytotoxicityDesignFat Emulsions, IntravenousFenretinideFormulations, DrugFundingGrantHematologic NeoplasmsInstitutionIntravenousLeukemiaMalignant Neoplasm Of OvaryNeuroblastomaOralPharmaceutical PreparationsResearch PersonnelResources
Grant awards (3)
PHASE I TRIAL OF INTRAVENOUS FENRETINIDE (4-HPR) FOR PATIENTS WITH HEMATOLOGI$155,024
M01 · FY2008 · RR · contact PI
PHASE I TRIAL OF INTRAVENOUS FENRETINIDE (4-HPR) FOR PATIENTS WITH HEMATOLOGI$125,016
M01 · FY2007 · RR · contact PI
PHASE I TRIAL OF INTRAVENOUS FENRETINIDE (4-HPR) FOR PATIENTS WITH HEMATOLOGI$121,932
M01 · FY2006 · RR · contact PI